Study of Targeted Therapy Using Transcription Activator-like Effector Nucleases in Cervical Precancerous Lesions

  • End date
    Jun 10, 2022
  • participants needed
  • sponsor
    Huazhong University of Science and Technology
Updated on 19 January 2022


This is an open-label and triple cohort study of the safety and efficacy of T27 and T512 to possibly treat cervical intraepithelial neoplasia(CIN).


Persistent infection with high-risk human papillomavirus (HPVs),especially types 16 and 18,may lead to cervical intraepithelial neoplasia(CIN).HPVs expresses the oncoproteins E6 and E7, both of which play key roles in maintaining viral infection and promoting carcinogenesis. Previous studies showed that using designated TALENs (T27 and T512) targeted HPV16 E6 and E7 produced disruption of HPV16 E6 and E7 DNA, decreased the expression of E6 and E7 proteins, and induced cell apoptosis.

This study will evaluate the safety and efficacy of T27 and T512 in treating HPV Persistency and HPV16-positive CIN.

Condition Human Papillomavirus-Related Malignant Neoplasm, Human Papillomavirus-Related Malignant Neoplasm
Treatment T27, T512
Clinical Study IdentifierNCT03226470
SponsorHuazhong University of Science and Technology
Last Modified on19 January 2022


Yes No Not Sure

Inclusion Criteria

Documented HPV16 or HPV18 infection
Married and fertile, no fertility requirements
Without administration of hormone in the last six months
Subjects must be meet the ethical requirements and have signed informed consent

Exclusion Criteria

Pregnancy and breast feeding
Any bacterial vaginitis
Any Fungal vaginitis
Any sexually transmitted diseases
Active drug or alcohol abuse
Any HPV medications within the past 12 weeks
Allergy to active or non active ingredients in the study of drugs
Cardiac insufficiency
Liver and renal insufficiency
Hypertension and severe complications
Serious illness in past 30 days
Currently participating in another clinical trial or any prior gene therapy
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note